Companies

Technology / Differentiation
Jaleva's patented resin technology allows medication to be delivered safely and more effectively into the bloodstream (via transbuccal route) and to the skin (topically) than traditional delivery vehicles.

Jaleva's resin technology is a formulation of specific resins (approved by the FDA) which combine with medication or an active ingredient. The formulation is applied topically on the skin or trans-mucosally and releases the medication over time.

Upcoming Products in Development

The products available for licensing, or in some cases co-development, include:

- Topical Naproxen Sodium

- Fast acting* transbuccal Ketorolac

- Fast acting* transbuccal Dihydroergotamine (as well as several triptans)

- Fast acting* transbuccal Vardenafil (Levitra)

- Fast acting* transbuccal Ondansetron (Zofran)

*In most cases onset is within minutes and tmax is between 10-20 minutes.  Transbuccal deliver is via a tiny drop placed via unit dose applicator on the inside of the cheek.

Jaleva is engaged in the research & development of topical delivery and trans-mucosal vehicles for active ingredients that treat:

smoking cessation, pain (Diclofenac, Naproxen Sodium, Ketorolac, anti-Migraine), as well as erectile dysfunction, anti-nausea (ondansetron)

We seek to license or partner with a firm that has a desire to market medication with our superior delivery system of the active ingredient.

Our FDA and European regulatory routes are short (505b2) since we enter a marketplace with an active ingredient already approved by the regulatory agencies.

Our IP is strong and covers our technology broadly.